Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cinacalcet hydrochloride (Sensipar).

Grace Poon1

  • 1Department of Pharmacy Services, Baylor University Medical Center, Dallas, Texas 75246, USA. gracep@BaylorHealth.edu

Proceedings (Baylor University. Medical Center)
|October 4, 2005
PubMed
Summary

Cinacalcet effectively reduces parathyroid hormone and calcium levels in patients with secondary hyperparathyroidism, offering a new treatment option for dialysis patients. This calcimimetic agent improves key markers without significant adverse effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conversational artificial intelligence for pre-procedural patient preparation: implementation, validation and patient satisfaction.

NPJ digital medicine·2026
Same author

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.

Oncotarget·2019
Same author

Implementation of an Automatic Stop Order and Initial Antibiotic Exposure in Very Low Birth Weight Infants.

American journal of perinatology·2016
Same author

Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.

Journal of medicinal chemistry·2007
Same author

White matter volume and anisotropy in preterm children: a pilot study of neurocognitive correlates.

Pediatric research·2007
Same author

Ibuprofen lysine (NeoProfen) for the treatment of patent ductus arteriosus.

Proceedings (Baylor University. Medical Center)·2007

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Over 300,000 patients with end-stage renal disease require dialysis.
  • Secondary hyperparathyroidism is a common complication, leading to renal osteodystrophy and organ failure.
  • Current treatments like vitamin D sterols and phosphate binders risk hypercalcemia, contributing to vascular calcification.

Purpose of the Study:

  • To evaluate the efficacy of cinacalcet in treating secondary hyperparathyroidism in patients with end-stage renal disease.
  • To assess cinacalcet's role in managing hypercalcemia associated with parathyroid carcinoma.
  • To determine the impact of cinacalcet on parathyroid hormone, calcium, phosphorus, and calcium-phosphate product levels.

Main Methods:

  • Clinical trials were conducted to assess cinacalcet's therapeutic effects.
  • The study involved patients with end-stage renal disease and secondary hyperparathyroidism.
  • Cinacalcet's mechanism of action involves increasing calcium-sensing receptor sensitivity.

Main Results:

  • Cinacalcet demonstrated effectiveness in reducing parathyroid hormone levels.
  • Significant reductions in serum calcium, phosphorus, and calcium-phosphate product were observed.
  • The drug is administered as a once-daily oral therapy.

Conclusions:

  • Cinacalcet is an effective treatment for secondary hyperparathyroidism and associated hypercalcemia.
  • It offers a novel therapeutic approach by modulating calcium-sensing receptors.
  • Adverse effects associated with cinacalcet are generally mild, supporting its clinical utility.

Related Experiment Videos